Regeneron Pharmaceuticals (REGN) FY2024 results: revenue $14.2 billion, up 8.3% on the year
Regeneron Pharmaceuticals, Inc. (REGN) reported revenue of $14.2 billion for fiscal 2024, the year ended 31 December 2024, up 8.3% on the year before. Net income was $4.4 billion, up 11.6%, and diluted earnings per share $38.34. The figures are the company's own, from the 10-K it filed with the SEC on 5 February 2025.
Revenue
$14.2 billion
+8.3% on the year
FY2017FY2024
Operating margin
28.1%
30.9% a year earlier
FY2017FY2024
Net income
$4.4 billion
+11.6% on the year
FY2017FY2024
Diluted EPS
$38.34
+10.3% on the year
FY2017FY2024
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Operating cash flow
4,420
4,594
5,015
-3.8%
Capital expenditure
756
719
590
+5.2%
Free cash flow
3,665
3,875
4,425
-5.4%
Free cash flow margin
25.8%
29.5%
36.3%
Cash from investing
-2,468
-3,185
-3,785
Cash from financing
-2,200
-1,790
-1,009
Depreciation and amortisation
483
421
341
+14.7%
Share-based compensation
983
885
725
+11.1%
Buybacks
2,603
2,235
2,083
+16.5%
Dividends paid
0.0
0.0
n/a
Diluted shares, weighted
115m
114m
114m
+1.2%
Balance sheet
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Shareholders' equity
29,354
25,973
22,664
+13.0%
Debt
1,984
1,983
1,981
+0.1%
Operating lease liabilities
204
68.7
55.8
+197.1%
Finance lease liabilities
720
720
720
0.0%
Other liabilities
5,497
4,336
3,793
+26.8%
Total liabilities and equity
37,759
33,080
29,214
+14.1%
Intangible assets
1,149
1,039
916
+10.6%
Investments
15,424
13,511
11,228
+14.2%
Cash and equivalents
2,488
2,730
3,106
-8.9%
Receivables
6,212
5,667
5,329
+9.6%
Inventory
3,087
2,580
2,402
+19.6%
Other assets
9,399
7,552
6,234
+24.4%
Total assets
37,759
33,080
29,214
+14.1%
10-K for the year ended 31 December 2024, filed 5 February 2025: the filing.